ArticleJournal of perinatology : official journal of the California Perinatal Association2026
Assessment of iron sufficiency in premature infants treated with darbepoetin using conventional and novel erythrocyte metrics.
Article in Journal of perinatology : official journal of the California Perinatal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveRandomized trials demonstrate that administering darbepoetin to extremely low birth weight (ELBW) neonates increases hematocrits and reduces or eliminates transfusions. However, further studies are needed regarding maintaining adequate iron during darbepoetin therapy. STUDY
designWe analyzed datasets from the Neonatal Research Network Darbe Trial and Intermountain Health to assess iron sufficiency during darbepoetin treatment. We tracked traditional markers of erythropoiesis (reticulocytes and RET-He), and novel markers of iron-limited erythropoiesis (Micro-R and HYPO-He).
resultsAmong the placebo recipients, RET-He fell over the first week (33.6 ± 0.5 pg to 27.4 ± 0.2 pg, p < 0.001). Darbepoetin recipients fell further (p < 0.0001). We identified a reciprocal relationship between rising reticulocytes and falling RET-He. The majority (83%) of darbepoetin recipients with a RET-He <25 pg had Micro-R and HYPO-He measurements indicating iron-sufficiency.
conclusionsTraditional and novel red cell markers together may better inform iron sufficiency during accelerated erythropoiesis.
Identifiers
42693254What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.